Hexa PR Wire · Trusted Press Release Distribution

Kodal Minerals reports significant progress at Bougouni lithium project in Mali

Hexa PR Wire · Press Release
2 min read
On this page
  1. Contact Details

–News Direct–

Kodal Minerals PLC (AIM:KOD) CEO Bernard Aylward joins Proactive’s Stephen Gunnion with details of the latest milestones at the Bougouni lithium project in southern Mali.

Aylward highlighted that the project has seen significant progress following the completion of a transaction last November, ensuring the development is fully funded, including Phase One development, exploration, and further developments. The integration of teams from Kodal Minerals and their joint venture partner, Hainan Mining, has led to engineering improvements for better recovery and optimisation of the project.

Work on Dense Media Separation (DMS) units and the crushing circuit has commenced, with mining contractors expected to mobilise soon. The initial focus will be on civil work, including site preparation and clearing, to ready the operation for commissioning in late October or November, aiming for full production by year-end.

Phase One of the project involves a quick development process with a capital expenditure of $65 million. Phase Two aims to extend the mine life to 10-15 years, increasing production to over 370,000 tonnes per annum by adding a flotation plant for processing ore from additional prospects.

Aylward said the project enjoys support from the Malian government and local communities, with the Environment Minister visiting the site and expressing satisfaction.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/kodal-minerals-reports-significant-progress-at-bougouni-lithium-project-in-mali-148897823

AnswersFrequently asked questions

More press releases

The Moving Company That Filled Its Sales Pipeline but Still Left Trucks Idle: Why CEOs Must Match Local, Long-Distance and Commercial Lead Demand to Actual Operating Capacity

The Moving Company That Filled Its Sales Pipeline but Still Left Trucks Idle: Why CEOs Must Match Local, Long-Distance and Commercial Lead Demand to Actual Operating Capacity

The Laboratory Record That Cannot Be Reconstructed: Why Iowa Researchers Need Better Sample Identification, Analytical Documentation and Data Traceability Before Scientific Results Can Be Trusted

The Laboratory Record That Cannot Be Reconstructed: Why Iowa Researchers Need Better Sample Identification, Analytical Documentation and Data Traceability Before Scientific Results Can Be Trusted

Guy Ritchie’s The Gentlemen Lives On in the Hollywood Pictures™ Wardrobe Archive

Guy Ritchie’s The Gentlemen Lives On in the Hollywood Pictures™ Wardrobe Archive

North Carolina Has 133 Hospitals Across 100 Counties. Twenty-Three of Those Counties Have None

North Carolina Has 133 Hospitals Across 100 Counties. Twenty-Three of Those Counties Have None

A Laboratory Report Says 98% Pure, but What Exactly Is 98%? Why Peptide Research Needs Four Different Measurements Before the Numbers Make Sense

A Laboratory Report Says 98% Pure, but What Exactly Is 98%? Why Peptide Research Needs Four Different Measurements Before the Numbers Make Sense

The Interstate Moving Route That Looks Profitable Until the Truck Comes Home Empty: How Moving Companies Should Evaluate Lead Costs, Return Loads and New Market Expansion

The Interstate Moving Route That Looks Profitable Until the Truck Comes Home Empty: How Moving Companies Should Evaluate Lead Costs, Return Loads and New Market Expansion

The Auction Car That Costs More After the Winning Bid: How Vehicle Release Deadlines, Carrier Access and Delivery Decisions Affect Automotive Inventory Profits

The Auction Car That Costs More After the Winning Bid: How Vehicle Release Deadlines, Carrier Access and Delivery Decisions Affect Automotive Inventory Profits

When a Laboratory Report Becomes a Marketing Claim: Why Peptide Purity, Scientific Evidence and Regulatory Approval Must Be Kept Separate

When a Laboratory Report Becomes a Marketing Claim: Why Peptide Purity, Scientific Evidence and Regulatory Approval Must Be Kept Separate